Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Taxus Cardium Pharmaceuticals Group Inc (OTC Pink - Limited Information:CRXM)

Delayed Data
As of Jan 23
 -0.0029 / -1.62%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Taxus Cardium Pharmaceuticals Group, Inc. is an advanced regenerative therapeutics company, which focuses on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to advancing coronary artery disease, and Excellagen, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.

Contact Information

Taxus Cardium Pharmaceuticals Group, Inc.
11750 Sorrento Valley Road
San Diego California 92121
P:(858) 436-1000
Investor Relations:



Individual stakeholders1.12%
Mutual fund holders--
Other institutional--

Top Executives

Christopher J. ReinhardChairman, President, CEO, CFO, Treasurer & CAO
Gabor M. RubanyiChief Scientific Officer
Lois A. ChandlerVice President-Biologics Development
Duane M. LinstromSecretary